n.a. (HITK)

43.49
0.01 0.02
NASDAQ
Prev Close 43.50
Open 43.50
Day Low/High 43.48 / 43.50
52 Wk Low/High 0.00 / 0.00
Volume 149.97K
Exchange NASDAQ
Market Cap 604.82M
Div & Yield N.A. (N.A)

Latest News

Akorn Receives FTC Clearance For Hi-Tech Pharmacal Acquisition

Akorn Receives FTC Clearance For Hi-Tech Pharmacal Acquisition

Akorn, Inc. (NASDAQ: AKRX) today announced that the U.

Hi-Tech Pharmacal Announces Settlement Regarding Texas Pricing Investigation

Hi-Tech Pharmacal Announces Settlement Regarding Texas Pricing Investigation

Hi-Tech Pharmacal Co., Inc.

HI-Tech Pharmacal is Now Oversold (HITK)

HI-Tech Pharmacal is Now Oversold (HITK)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Acquisition Of Hi-Tech Pharmacal Co., Inc. (HITK) By Akorn, Inc. (AKRX) May Be Detrimental To The Interests Of Hi-Tech Pharmacal Co., Inc. Shareholders

Acquisition Of Hi-Tech Pharmacal Co., Inc. (HITK) By Akorn, Inc. (AKRX) May Be Detrimental To The Interests Of Hi-Tech Pharmacal Co., Inc. Shareholders

Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Hi-Tech Pharmacal Co., Inc.

HI-TECH PHARMACAL SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Launches An Investigation Of Hi-Tech Pharmacal Co., Inc. (HITK) Over The Proposed Sale Of The Company To Akorn, Inc. (AKRX)

HI-TECH PHARMACAL SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Launches An Investigation Of Hi-Tech Pharmacal Co., Inc. (HITK) Over The Proposed Sale Of The Company To Akorn, Inc. (AKRX)

Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Hi-Tech Pharmacal Co.

Short Interest In HI-Tech Pharmacal Plummets 68.8%

Short Interest In HI-Tech Pharmacal Plummets 68.8%

The most recent short interest data has been released by the NASDAQ for the 08/30/2013 settlement date, which shows a 684,585 share decrease in total short interest for HI-Tech Pharmacal Co., Inc. , to 310,607, a decrease of 68.79% since 08/15/2013.

SHAREHOLDER ALERT: Law Office Of Brodsky & Smith, LLC Announces Investigation Of Hi-Tech Pharmacal Co.

SHAREHOLDER ALERT: Law Office Of Brodsky & Smith, LLC Announces Investigation Of Hi-Tech Pharmacal Co.

Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Hi-Tech Pharmacal Co.

SHAREHOLDER ALERT: Law Office Of Brodsky & Smith, LLC Announces Investigation Of Hi-Tech Pharmacal Co.

SHAREHOLDER ALERT: Law Office Of Brodsky & Smith, LLC Announces Investigation Of Hi-Tech Pharmacal Co.

Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Hi-Tech Pharmacal Co.

Faruqi & Faruqi, LLP, Partner Juan E. Monteverde Launches An Investigation Of Hi-Tech Pharmacal Co., Inc. Over The Proposed Sale Of The Company To Akorn, Inc.

Faruqi & Faruqi, LLP, Partner Juan E. Monteverde Launches An Investigation Of Hi-Tech Pharmacal Co., Inc. Over The Proposed Sale Of The Company To Akorn, Inc.

Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Hi-Tech Pharmacal Co.

Law Firm Kirby McInerney LLP Investigating Potential Claims On Behalf Of Hi-Tech Pharmacal Co., Inc. Shareholders

Law Firm Kirby McInerney LLP Investigating Potential Claims On Behalf Of Hi-Tech Pharmacal Co., Inc. Shareholders

Kirby McInerney LLP is investigating potential claims against the Board of Directors of Hi-Tech Pharmacal Co.

Attention HITK Shareholders: The Proposed Buyout Of Hi-Tech Pharmacal Co., Inc. By Akorn, Inc. Under Investigation By The Young Law Firm

Attention HITK Shareholders: The Proposed Buyout Of Hi-Tech Pharmacal Co., Inc. By Akorn, Inc. Under Investigation By The Young Law Firm

The Young Law Firm, a leading national shareholder litigation firm, is investigating possible claims concerning the proposed acquisition of Hi-Tech Pharmacal Co.

Stocks Plummet on Prospect of U.S.-Led Airstrike on Syria

Stocks Plummet on Prospect of U.S.-Led Airstrike on Syria

A better-than-expected consumer confidence report for August couldn't shake concern that a U.S. airstrike in Syria could escalate Middle East wars, disrupting oil supplies.

Hi-Tech Pharmacal Shareholder Alert: The Briscoe Law Firm And Powers Taylor, LLP Investigate Acquisition By Akorn, Inc.

Hi-Tech Pharmacal Shareholder Alert: The Briscoe Law Firm And Powers Taylor, LLP Investigate Acquisition By Akorn, Inc.

Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor, LLP are investigating the acquisition of Hi-Tech Pharmacal Co.